Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.62 USD
Change Today -0.02 / -0.76%
Volume 46.4K
DSKX On Other Exchanges
As of 8:10 PM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

ds healthcare group inc (DSKX) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/19/15 - $4.96
52 Week Low
12/22/14 - $0.56
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DS HEALTHCARE GROUP INC (DSKX)

Related News

No related news articles were found.

ds healthcare group inc (DSKX) Related Businessweek News

No Related Businessweek News Found

ds healthcare group inc (DSKX) Details

DS Healthcare Group, Inc., doing business as DS Laboratories, develops and markets hair care, skin care, and personal care products in North America and internationally. Its hair care products include Revita and Revita LT shampoos, and Revita.Cor conditioner for hair growth stimulation; Dandrene, an antifungal shampoo to treat itchy scalp and dandruff; and Spectral line of products comprising Spectral.DNC spray formula, Spectral.DNC-L lotion, and Spectral DNC-N to re-grow hair through various pathways, as well as Spectral.RS, a topical treatment for men and women with advanced androgenic alopecia. The company’s skin care products comprise Hydroviton, a skin cleanser for oily and acne prone skin; Keramene, which is used to suppress hair growth and soften remaining hair strands; Oligo.DX, a cream to enhance the appearance of cellulite from women’s thighs, hips, and buttocks; and Trioxil, an acne cream. Its personal care products consist of Nirena, an intimate feminine care cleanser; and Spectral Lash, a product based on advanced bio-peptides that are designed to grow and enhance the length and girth of eyelash hair. DS Healthcare Group, Inc. markets and sells its products under the DS Laboratories, Polaris Labs, and Sigma Skin brands through salons, spas, department stores, specialty retailers, and distributors. The company was formerly known as Divine Skin, Inc. and changed its name to DS Healthcare Group, Inc. in November 2012. DS Healthcare Group, Inc. is headquartered in Pompano Beach, Florida.

46 Employees
Last Reported Date: 04/15/15

ds healthcare group inc (DSKX) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2014.

ds healthcare group inc (DSKX) Key Developments

DS Healthcare Group, Inc., WR Group, Inc. - M&A Call

To discuss definitive agreement ?to acquire WR Group

DS Healthcare Group Appoints Manuel Gonzalez as Chief Commercial Officer

DS Healthcare Group, Inc. has announced that Manuel Gonzalez, a former Vice President of Sales for the Procter & Gamble Company has joined DS Healthcare as its Chief Commercial Officer. In his role at Procter & Gamble, Mr. Gonzalez was responsible for managing an organization with $30 billion in revenue including the entire North American merchandiser sales force of over 3,000 sales representatives for all Procter & Gamble product categories, including the company’s extensive personal care products portfolio. Mr. Gonzalez has joined the management team at DS Healthcare to help rapidly scale sales operations of DS Healthcare’s innovative personal care products due to his extensive experience managing massive retail operations and his knowledge of every significant retail channel in the United States and South America.

DS Healthcare Group, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

DS Healthcare Group, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. The company's net revenues were $3,659,548, a decrease of 2.3% over revenues of $3,744,434 in the year-earlier period. Revenue in the second quarter was affected by an unfavorable exchange rate of the Mexican Peso to the USD which was MXN 15.65 to the Dollar at the end of the second quarter and MXN 12.95 to the Dollar during the same period 2014. GAAP net loss narrowed by 98.4% to a net loss of $9,551 in the second quarter of 2015 compared to a net loss $635,172 in the same period of 2014. Adjusted EBITDAS was $116,313 compared to a loss of $781,096 in the year-earlier period. For the six months ended June 30, 2015 net revenues were $6,463,468, a 0.5% increase from revenues of $6,429,397 for the six months ended June 30, 2014. Net revenue was driven in part by the company's Mexican subsidiary, as well increased sell-through in foreign markets but was offset by a stronger dollar compared to foreign currencies. Net loss decreased by 93.5% to $94,690 in the first half of 2014 from $1,453,324 in the same period of 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSKX:US $2.62 USD -0.02

DSKX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Johnson & Johnson $93.42 USD -1.34
Procter & Gamble Co/The $73.40 USD +0.18
View Industry Companies

Industry Analysis


Industry Average

Valuation DSKX Industry Range
Price/Earnings 100.0x
Price/Sales 3.3x
Price/Book 7.6x
Price/Cash Flow 604.4x
TEV/Sales 3.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DS HEALTHCARE GROUP INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at